Article
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
Nature medicine - 1 Feb 2021
Rozeman E A, Hoefsmit E P, Reijers I L M, Saw R P M, Versluis J M, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel B A, Eriksson H, Gonzalez M, Torres Acosta A, Grijpink-Ongering L G, Shannon K, Haanen J B A G, Stretch J, Ch'ng S, Nieweg O E, Mallo H A, Adriaansz S, Kerkhoven R M, Cornelissen S, Broeks A, Klop W M C, Zuur C L, van Houdt W J, Peeper D S, Spillane A J, van Akkooi A C J, Scolyer R A, Schumacher T N M, Menzies A M, Long G V, Blank C U
Abstract excerpt
Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies1,2. While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking. After a median follow-up of 4 years, none of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.